Metabolic Disorders in the Myocardia in the Background of Chemotherapeutic Treatment of Breast Cancer and Ways of Correction

Abstract

In recent years, there has been significant progress in the treatment of breast cancer associated with the development of new chemotherapeutic drugs. More often, they are used in combination with classical chemotherapy regimens, including doxorubicin. Against the background of such combined treatment, a significant increase in the life expectancy of patients was noted, but at the same time, the risk of cardiotoxic action significantly increases. The review provides information on disorders of cardiomyocyte metabolism during anthracycline therapy, discusses the possibilities of pathogenetic treatment and prevention.